Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2021 19:18 ET | Source: Mesoblast Limited

Update on Novartis Agreement

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it...
December 05, 2021 18:47 ET | Source: Mesoblast Limited

Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia

Key points: Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest...
November 23, 2021 18:09 ET | Source: Mesoblast Limited

Operational Highlights and Financial Results for the Period Ended September 30, 2021

NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
November 23, 2021 07:18 ET | Source: Mesoblast Limited

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
November 21, 2021 19:31 ET | Source: Mesoblast Limited

Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has...
November 14, 2021 19:13 ET | Source: Mesoblast Limited

Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure

Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Inflammation NEW YORK, Nov. 14, 2021 (GLOBE NEWSWIRE) --...
October 28, 2021 19:51 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
October 18, 2021 08:00 ET | Source: Mesoblast Limited

Remestemcel-L Improves Survival of Children With Biomarkers for Highest Mortality in Steroid Refractory Acute GVHD

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results published...
October 06, 2021 20:38 ET | Source: Mesoblast Limited

Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as Late Breaking Presentation at American Heart Association Annual Meeting

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the...
August 30, 2021 19:38 ET | Source: Mesoblast Limited

Operational Highlights and Financial Results for the Year Ended June 30, 2021

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right